Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02893943
Other study ID # B2016:033
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 1, 2017
Est. completion date January 31, 2018

Study information

Verified date April 2021
Source University of Manitoba
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the study is to evaluate the potential of probiotics on weight management. It is hypothesized that the consumption of 1 capsule of probiotics daily will modulate the intestinal gut microbiota thereby reducing body weight and fat compared to those who do not consume probiotics. In addition, a diet supplemented with probiotics can be expected to be more beneficial than a diet without probiotic supplementation in impacting biomarkers of obesity-associated disorders including diabetes, hypertension and cardiovascular disease (CVD).


Description:

Overweight, obese men and women volunteers aged between 18-65 yrs with BMI greater than or equal to 25 will be recruited from the Winnipeg (Manitoba, Canada) area to participate in a two arm crossover, randomized, double-blind, placebo-controlled, free-living intervention study for 60 days per study period following obtainment of informed consent. Participants will be informed to maintain their usual diets as well as their physical activity level. After obtaining consent, participants will be randomized to receive either 1 capsule containing probiotics, or 1 capsule of placebo daily for 60 days. Compared with the probiotic capsules, the placebo contains the same carrier material and is similar in size, shape and taste.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date January 31, 2018
Est. primary completion date July 31, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Overweight, obese men and women volunteers aged between 18-65 yrs - BMI equal to or greater than 25 - Willingness to complete questionnaires, records, and diaries associated with the study and to complete all clinic visits. - Willingness to discontinue consumption of fermented foods or probiotics (e.g. yoghourts, with live, active cultures or supplements), laxatives, prebiotics and any substances for control body weight. - Able to provide informed consent. - Women of childbearing potential with a negative pregnancy test at screening. Exclusion Criteria - BMI greater than 35 - Previous history of cardiovascular disease, diabetes, liver or kidney disease, inflammatory bowel disease, celiac disease, short bowel syndrome, any malabsorptive syndrome, pancreatitis, gallbladder or biliary disease. - Those currently taking (or have taken within the last 3 months) cholesterol-lowering, triglyceride-lowering or hypertension medications. - Those currently taking (or have taken within the last 3 months) lipid-lowering supplements, (e.g., omega-3 supplements, plant sterols/stanols foods and/or supplements, fibre, etc). - Smokers. - Allergic to milk, soy, or yeast (some of our probiotics strains may contains these items). - Use of another investigational product within 3 months of the screening visit. - Positive pregnancy test in women of child-bearing potential. - Known to be pregnant or breast-feeding or planning on becoming pregnant in the next 18 months. - Women of child-bearing potential not using effective contraception. - Use of any other treatments (medication or nutritional program) affecting body weight, food intake and/or energy expenditure. - Menopausal women. - Weight gain or loss of at least 10lbs in previous three months. - Uncontrolled angina within the past six months. - Cancer treatment (radiation, chemotherapy, surgery) within past six months or any other treatment or condition known to weaken the immune system (such as systemic corticosteroids or HIV/AIDS). - Any physical condition deemed likely to significantly interfere with individuals' ability to participate in a nutritional intervention. - Currently or at any point during the study participating in Weight Watcher's or another weight loss program or taking a medication for weight loss. - History of drug or alcohol (> 2 drinks daily) abuse. - Abnormal thyroid hormone levels. - Immune-compromised conditions. - Participant experiencing nausea, fever, vomiting, bloody diarrhoea or severe abdominal pain (past week and chronic). - Participants exercising > 15 miles/wk or 4,000 kcal/wk.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Probiotics

Placebo


Locations

Country Name City State
Canada Richardson Centre for Functional Foods and Nutraceuticals Winnipeg Manitoba

Sponsors (2)

Lead Sponsor Collaborator
University of Manitoba Lallemand Health Solutions

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Body weight 60 days
Secondary Body mass index 60 days
Secondary Body fat percentage 60 days
Secondary Waist circumference 60 days
Secondary Hip circumference 60 days
Secondary Total fat mass 60 days
Secondary Total lean mass 60 days
Secondary Gut microbiome Stool samples will be collected from participants to analyze intestinal microbiota community composition 60 days
Secondary Blood pressure 60 days
Secondary Blood total cholesterol 60 days
Secondary Blood low-density lipoprotein cholesterol 60 days
Secondary Blood high-density lipoprotein cholesterol 60 days
Secondary Blood triglycerides 60 days
Secondary Blood glucose 60 days
Secondary Blood insulin 60 days
Secondary Aspartate aminotransferase 60 days
Secondary Alanine transaminase 60 days
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2